Last reviewed · How we verify

Pancrelipase Capsules

Ohio State University · FDA-approved active Small molecule

Pancrelipase Capsules is a Pancreatic enzyme replacement therapy Small molecule drug developed by Ohio State University. It is currently FDA-approved for Pancreatic exocrine insufficiency due to chronic pancreatitis, Pancreatic exocrine insufficiency due to cystic fibrosis, Pancreatic exocrine insufficiency due to pancreatic surgery or obstruction. Also known as: CREON.

Pancrelipase is a mixture of pancreatic enzymes (lipase, protease, and amylase) that replaces deficient endogenous pancreatic enzymes to restore normal digestion of fats, proteins, and carbohydrates.

Pancrelipase is a mixture of pancreatic enzymes (lipase, protease, and amylase) that replaces deficient endogenous pancreatic enzymes to restore normal digestion of fats, proteins, and carbohydrates. Used for Pancreatic exocrine insufficiency due to chronic pancreatitis, Pancreatic exocrine insufficiency due to cystic fibrosis, Pancreatic exocrine insufficiency due to pancreatic surgery or obstruction.

At a glance

Generic namePancrelipase Capsules
Also known asCREON
SponsorOhio State University
Drug classPancreatic enzyme replacement therapy
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

Pancrelipase contains lipase, protease, and amylase derived from porcine pancreatic tissue. These enzymes are essential for breaking down dietary macronutrients in the small intestine. In patients with pancreatic insufficiency, endogenous enzyme production is inadequate, leading to malabsorption; pancrelipase supplementation restores digestive capacity and nutrient absorption.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pancrelipase Capsules

What is Pancrelipase Capsules?

Pancrelipase Capsules is a Pancreatic enzyme replacement therapy drug developed by Ohio State University, indicated for Pancreatic exocrine insufficiency due to chronic pancreatitis, Pancreatic exocrine insufficiency due to cystic fibrosis, Pancreatic exocrine insufficiency due to pancreatic surgery or obstruction.

How does Pancrelipase Capsules work?

Pancrelipase is a mixture of pancreatic enzymes (lipase, protease, and amylase) that replaces deficient endogenous pancreatic enzymes to restore normal digestion of fats, proteins, and carbohydrates.

What is Pancrelipase Capsules used for?

Pancrelipase Capsules is indicated for Pancreatic exocrine insufficiency due to chronic pancreatitis, Pancreatic exocrine insufficiency due to cystic fibrosis, Pancreatic exocrine insufficiency due to pancreatic surgery or obstruction.

Who makes Pancrelipase Capsules?

Pancrelipase Capsules is developed and marketed by Ohio State University (see full Ohio State University pipeline at /company/ohio-state-university).

Is Pancrelipase Capsules also known as anything else?

Pancrelipase Capsules is also known as CREON.

What drug class is Pancrelipase Capsules in?

Pancrelipase Capsules belongs to the Pancreatic enzyme replacement therapy class. See all Pancreatic enzyme replacement therapy drugs at /class/pancreatic-enzyme-replacement-therapy.

What development phase is Pancrelipase Capsules in?

Pancrelipase Capsules is FDA-approved (marketed).

What are the side effects of Pancrelipase Capsules?

Common side effects of Pancrelipase Capsules include Abdominal pain, Nausea, Diarrhea, Constipation, Hyperuricemia.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing